Results 11 to 20 of about 4,421 (195)
Journal of Mahatma Gandhi Institute of Medical Sciences, 2013 Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia.
Vishakha V Jain, Omprakash Gupta
doaj +3 more sources
Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
Indian Journal of Endocrinology and Metabolism, 2016 This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast.
Sanjay Kalra
doaj +4 more sources
Efficacy and safety of ultra-long-acting insulin degludec
Therapeutic Advances in Endocrinology and Metabolism, 2012 All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control.
Ammar Wakil, Stephen L. Atkin
doaj +2 more sources
Glargine and degludec: Solution behaviour of higher dose synthetic insulins [PDF]
Scientific Reports, 2017 Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt ...
Gary G. Adams +10 more
doaj +4 more sources
Insulin degludec is a new ultra-long-acting insulin analogue [PDF]
Сахарный диабет, 2014 Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment.
Ivan Ivanovich Dedov +1 more
doaj +2 more sources
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Drug Design, Development and Therapy, 2017 Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj +1 more source
Journal of Diabetes Research, 2022 Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory
Yuki Oe +11 more
doaj +2 more sources
Therapeutic Advances in Endocrinology and Metabolism, 2018 Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec.
Scott M. Pearson, Jennifer M. Trujillo
doaj +2 more sources
Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population [PDF]
Journal of Diabetes Investigation, 2022 We report the findings of a single‐dose, randomized, three‐period cross‐over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components. Furthermore, we
Hongzhong Liu +6 more
doaj +3 more sources
IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis [PDF]
Frontiers in EndocrinologyObjectivesThis systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).MethodsA comprehensive search was systematically conducted ...
Yang Liu +6 more
doaj +2 more sources